Up to date at 9:59 am EST
Johnson & Johnson (JNJ) – Get Johnson & Johnson Report posted stronger-than-expected first quarter earnings Tuesday however lowered its full-year revenue forecast, and suspended its steerage for vaccine gross sales amid what it known as a world surplus and waning demand.
Johnson & Johnson stated adjusted earnings for the three months ending in March had been pegged at $2.67 per share, up 3% from the identical interval final yr and eight cents forward of the Road consensus forecast. Group revenues, Johnson & Johnson stated, rose 45% to $23.43 billion, a determine that simply missed analysts’ estimates of a $23.6 billion tally.
Pharmaceutical gross sales rose 9.3%, however missed forecasts thanks partially to slowing vaccine gross sales, whereas medical devise gross sales rose 8.5% and beat the Road by round $425 million.
The group additionally elevated its quarterly dividend by 6.6%, to $1.13 per share.
Wanting into the 2022 monetary yr, Johnson & Johnson stated it sees adjusted earnings within the area of $10.15 to $10.35 per share, down from its prior forecast of $10.40 to $10.60 per share, with gross sales within the area of $94.8 to $95.8 billion. That is down from its earlier estimate of $98.9 billion to $100.4 billion, though that tally included vaccine gross sales.
Scroll to Proceed
“Our first quarter outcomes display sturdy efficiency throughout the enterprise, regardless of macro-economic headwinds. I’m extremely happy with Johnson & Johnson’s 144,000 workers for his or her relentless ardour and Credo-based dedication to delivering transformative healthcare options to sufferers and clients around the globe,” stated CEO Joaquin Duato. “Wanting forward, I stay assured in the way forward for Johnson & Johnson as we proceed advancing our portfolio and progressive pipeline.”
Johnson & Johnson shares had been marked 4% larger in early Tuesday buying and selling instantly following the earnings launch to vary fingers at $184.76 every, a transfer that extends the inventory’s year-to-date achieve to round 7.7%. The inventory hit an all-time excessive of $185.94 earlier within the session.
Johnson & Johnson continues to face legal responsibility dangers linked to each its position within the U.S. opioid disaster and the sale of talc-based merchandise that some courts have dominated contained cancer-causing asbestos.
The group has reached a settlement with a set of state attorneys normal — together with AmerisourceBergen Corp ACB, McKesson Corp MCK and Cardinal Well being — that would concerned funds of as a lot as $26 billion for its half within the opioid epidemic.
Johnson & Johnson stated in late November that it’ll spin-off its client well being division — which incorporates manufacturers similar to Band-Support, Child Powder and Tylenol and is prone to generate $15 billion in revenues this yr — from its pharmaceutical and medical gadgets division over the subsequent 18 to 24 months.
Moody’s Buyers Providers stated Johnson & Johnson could lose its coveted triple-A credit standing following the spin-off, leaving Microsoft MSFT as the one American firm with the best debt grade.
Liabilities tied to courtroom rulings on tac product legal responsibility, that are prone to stay with the patron well being group, would additionally “characterize an overhang to J&J’s in any other case glorious credit score high quality.”
Johnson & Johnson famous in October that prices linked to defending 40,000 instances linked to allegations that its Child Powder, and different talc-based merchandise, contained cancer-causing asbestos are near $1 billion. One other $3.5 billion has been tied to earlier verdicts and settlements.